Fosamax and Osteonecrosis of the Jaw: Legal Considerations for New York Patients

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Awareness

For decades, general health and science information has served as the foundation for public understanding of medication safety and disease prevention. In this legacy context, broad awareness campaigns and educational materials have guided patients and providers toward informed decisions about therapeutic options. As the landscape of pharmaceutical knowledge evolves, specific concerns emerge that require focused attention beyond general health advisories. One such area involves the long-term use of bisphosphonate medications, originally developed to address bone density loss, and the subsequent recognition of rare but serious adverse effects. Among these, osteonecrosis of the jaw has been identified as a condition associated with exposure to drugs like Fosamax, particularly in patients undergoing dental procedures or with certain risk factors. This shift from general health education to targeted risk awareness necessitates a careful examination of exposure patterns, especially in occupational settings where healthcare professionals, dental workers, and pharmaceutical manufacturing employees may encounter these compounds repeatedly. The transition from broad public health messaging to specific occupational exposure concern is therefore critical, as it reframes the discussion from population-level guidance to individual risk assessment in work environments. Understanding the implications of such exposure, including legal considerations such as statutes of limitations for filing claims in jurisdictions like New York, becomes paramount for those affected.

Medical Evidence Linking Fosamax to Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined; for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a known adverse effect associated with bisphosphonate therapy, including Fosamax. ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is rare; one study reported that the incidence of atypical femoral fracture or osteonecrosis of the jaw was uncommon and rare, respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years, after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/).

Clinical Presentation and Mechanisms of ONJ

The clinical presentation of ONJ typically involves exposed necrotic bone in the maxillofacial region, often with pain, swelling, and infection. Diagnosis is based on clinical examination and imaging, with a history of bisphosphonate use being a key factor. The mechanistic pathways linking Fosamax to ONJ are thought to involve suppression of bone turnover due to inhibition of osteoclast activity, leading to impaired bone remodeling and repair, particularly in the jawbone which has high turnover rates. This can result in microdamage accumulation and necrosis, especially when combined with local factors such as dental procedures or infection. Regarding the adequacy of warnings, the Fosamax label includes a specific section on osteonecrosis of the jaw, describing its association with bisphosphonates, risk factors, and recommendations for dental care (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, patients and healthcare providers may not always be fully aware of these risks, particularly the need for dental evaluation before starting therapy and the potential for ONJ to occur even after discontinuation.

Statute of Limitations for Fosamax Claims in New York

For affected patients in New York, attorney-related considerations involve the statute of limitations for filing a product liability claim. In New York, the statute of limitations for personal injury claims is generally three years from the date of injury. However, the timeline between exposure to Fosamax and documented harm can be complex, as ONJ may develop months to years after starting the drug, and symptoms may not be immediately recognized as drug-related. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), but the condition can also occur after longer exposure. Patients should consult with an attorney to determine the applicable statute of limitations based on their specific circumstances, including the date of diagnosis and when the injury was or should have been discovered. In summary, Fosamax is associated with a rare but serious risk of ONJ, with known risk factors and a variable time to onset. The drug label provides warnings, but patients should be vigilant about dental health and seek legal advice if they develop ONJ after Fosamax use, particularly regarding New York's statute of limitations.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in New York?

In New York, the statute of limitations for personal injury claims is generally three years from the date of injury. However, because ONJ may develop months to years after starting Fosamax, the discovery rule may apply, meaning the clock starts when the injury is or should have been discovered. It is crucial to consult with an attorney to determine the exact deadline based on your specific circumstances.

What are the known risk factors for developing ONJ from Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.